About Us

Michael Harte

Michael Harte, Founder
The Harte Group

The Harte Group has a global network of more than 140 functional service providers that employ more than 16,000 professionals – with an average of nearly 20 years of experience and specific expertise to help pharmaceutical, biotechnology and medical device companies conduct clinical research.

“Many sponsors leverage Clinical Research Organizations (CROs) for clinical trial strategy and execution, retaining core competency to manage smaller, more nimble organizations,” says President and Founder Michael Harte.  “We help these groups select, qualify and oversee selected CRO partners – and ensure that the selected vendors perform in terms of services, deliverables and quality.

“Our team will strategize around your projects and identify CRO partners who appreciate your operating environment, business culture and staff to pair you with like-minded individuals and companies.”

Because The Harte Group has outstanding people and vendors, optimized processes and integrated technology, it can offer transparency and embrace its sponsors and network as one unit to generate creative ideas, solve problems and execute studies – and ensure the success of today’s smaller, earlier clinical trials.

About the Founder

Michael Harte has more than 20 years of experience in the CRO services industry.  Through his work with two traditional global CRO services companies, Harte excelled at exploiting the sponsor/vendor interface, ensuring that expectations of services and communication channels were established, leading to many years of services support for its company’s clients.

Seeing the newer trends evolve, Harte was a co-founder of one of the first electronic data collection (EDC) companies in the industry, and helped to steer the company and its clients to push the boundaries of simple data collection to an integrated platform that allowed clients to effectively use the information to effectively manage their internal and external resources.

Harte founded The Harte Group in 2009 with other like-minded industry executives who have an average of 24 years experience to assist companies who are implementing a virtual solution to their drug development challenges.